InMed Pharmaceuticals (INM) Enterprise Value (2020 - 2026)

InMed Pharmaceuticals' Enterprise Value history runs 7 years deep, the most recent figure standing at -$5.2 million for Q1 2026.

• On a quarterly basis, Enterprise Value fell 10.57% year-over-year to -$5.2 million in Q1 2026; TTM through Mar 2026 was -$5.2 million, a 10.57% decrease from a year earlier, with the FY2025 full-year figure at -$10.8 million, down 63.07% from the prior year.
• Enterprise Value improved to -$5.2 million in Q1 2026 per INM's latest filing, from -$7.0 million in the prior quarter.
• Across five years, Enterprise Value topped out at -$1.3 million in Q3 2024 and bottomed at -$11.5 million in Q4 2022.
• The 5-year median for Enterprise Value is -$6.6 million (2024), against an average of -$6.8 million.
• Across the five-year window, Enterprise Value surged 88.23% in 2023 and slumped 632.31% in 2025, its largest moves.
• Year by year, Enterprise Value stood at -$11.5 million in 2022, then jumped by 88.23% to -$1.4 million in 2023, then tumbled by 224.37% to -$4.4 million in 2024, then sank by 60.54% to -$7.0 million in 2025, then climbed by 25.57% to -$5.2 million in 2026.
• Per Business Quant, the three latest INM Enterprise Value figures stand at -$5.2 million (Q1 2026), -$7.0 million (Q4 2025), and -$9.4 million (Q3 2025).